Validation of the Experience Sampling Dietary Assessment Method
Launched by KU LEUVEN · Jun 26, 2024
Trial Information
Current as of August 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new way to track what people eat, called the Experience Sampling Dietary Assessment Method (ESDAM). Researchers want to make sure this method is accurate and reliable by comparing it with other well-established ways of measuring diet. The goal is to see if ESDAM can be used effectively in research and healthcare settings to help understand people's eating habits.
To participate in this study, you need to be between the ages of 65 and 74, have a smartphone, and be comfortable using apps. You should also have a freezer at home and be able to understand Dutch. It's important that your weight has been stable (not changing by more than 5%) in the last three months, and you should not be trying to lose or gain weight during the study. If you are pregnant, breastfeeding, or on a special diet for medical reasons, you won’t be able to join. If you take part, you will help researchers develop a tool that could improve how dietary habits are measured in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed informed consent
- • Having a smartphone and being capable of using the smartphone and apps
- • Having a freezer at home
- • Sufficient knowledge of the Dutch language to understand and participate in the study
- • Having a stable body weight (body weight not changed by 5% last 3 months)
- • Not aiming to gain or lose weight during the study period
- Exclusion Criteria:
- • Pregnant or lactating women
- • Not following a specific diet for medical reasons (i.e. coeliac disease)
About Ku Leuven
KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Christophe Matthys, PhD
Principal Investigator
KU Leuven/UZ Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported